Tara Hart
Family · Owensboro, KYNPI 1134726284
Payments from drug & device makers
Across 95 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$425
- AstraZeneca$213
- Lilly USA, LLC$179
- Novo Nordisk$167
- Vanda Pharmaceuticals Inc.$153
- Gilead$98
- plus $527 from 19 others
What the payments were for
- Food & beverage$1,763100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $425 |
| AstraZeneca | 6 | $213 |
| Lilly USA, LLC | 14 | $179 |
| Novo Nordisk | 10 | $167 |
| Vanda Pharmaceuticals Inc. | 2 | $153 |
| Gilead | 5 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Xeris Pharmaceuticals, Inc. | 4 | $72 |
| Sumitomo Pharma America, Inc. | 3 | $62 |
| Alkermes, Inc. | 2 | $47 |
| Amgen | 3 | $43 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Medtronic | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Cipher Pharmaceuticals US LLC | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Bayer | 1 | $14 |
| Recordati_rare_diseases_inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Insulet Corporation | 1 | $12 |
| Endogastric Solutions, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,763 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 20 | $16,250 |
| OzempicSemaglutide | 12 | $13,872 |
| SynthroidLevothyroxine Sodium | 14 | $812 |
| Levothyroxine Sodium | 48 | $546 |
| Potassium Chloride | 32 | $530 |
| Omeprazole | 29 | $397 |
| Atorvastatin Calcium | 48 | $313 |
| Ropinirole Hcl | 26 | $241 |
| Rosuvastatin Calcium | 35 | $230 |
| Lisinopril | 62 | $219 |
| Pantoprazole Sodium | 23 | $190 |
| Metformin Hcl | 52 | $187 |
| Carvedilol | 12 | $180 |
| Pioglitazone Hcl | 11 | $150 |
| Furosemide | 32 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $213 | $16,25020 claims |
| Novo NordiskOzempic | $167 | $13,87212 claims |
| AbbVieSynthroid | $425 | $81214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.
Other family in Owensboro
- Jason SandersOwensboro$30K
- Melanie McCartyOwensboro$15K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.